Top Tweets for #atempt

BREAST CANCER CONNECT powered by COR2ED

over 1 year ago

We are leading a randomized Phase 2 trial for stage 1 HER2+ #BreastCancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (#ATEMPT 2.0). For more information call 877-338-7425 or visit: https://t.co/CQRaG5zFfb

DFCI_BreastOnc's tweet photo. We are leading a randomized Phase 2 trial for stage 1 HER2+ #BreastCancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (#ATEMPT 2.0).
For more information call 877-338-7425 or visit:
https://t.co/CQRaG5zFfb https://t.co/TK8FjScKcb

1

11

3

1K

@BreastCaConnect

almost 2 years ago

🔁 Important findings from the #ATEMPT trial on Stage I HER2-positive #BreastCancer! Explore the 5-year results comparing adjuvant Trastuzumab Emtansine vs. Paclitaxel + Trastuzumab. #MedEd Check out the full study below👇 https://t.co/ll0knM2maP

almost 2 years ago

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉https://t.co/5l3sVrg6Av @PTarantinoMD @stolaney1 @NabihahTayob @adawaksmd @awolff

DFCI_BreastOnc's tweet photo. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT
👉https://t.co/5l3sVrg6Av
@PTarantinoMD @stolaney1 @NabihahTayob @adawaksmd @awolff https://t.co/9QWmHXekxG

1

47

19

21

7K

0

6

3

0

2K

almost 2 years ago

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉https://t.co/5l3sVrg6Av @PTarantinoMD @stolaney1 @NabihahTayob @adawaksmd @awolff

1

47

19

21

7K

about 2 years ago

Thanks to the @ASCOPost for featuring our JCO publication of the #ATEMPT 5y update! With <1% risk of distant recurrence at 5 years & improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC. https://t.co/arPPCAuFNh

PTarantinoMD's tweet photo. Thanks to the @ASCOPost for featuring our JCO publication of the #ATEMPT 5y update! With <1% risk of distant recurrence at 5 years & improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC. https://t.co/arPPCAuFNh https://t.co/voSTif7ys8

1

70

21

16

6K

about 2 years ago

Nearly 1000 downloads in less than a week for our #ATEMPT 5-year publication Thanks to @JCO_ASCO for including it in the Featured Content! https://t.co/1Jo0Ot03xb

PTarantinoMD's tweet photo. Nearly 1000 downloads in less than a week for our #ATEMPT 5-year publication

Thanks to @JCO_ASCO for including it in the Featured Content!

https://t.co/1Jo0Ot03xb https://t.co/l0eQ5iIQUQ

about 2 years ago

Can ADCs help prevent BC relapse with maintained QoL? Glad to share the final analysis of ATEMPT, out in JCO: among 383 pts with stage I HER2+ BC receiving T-DM1, 5y iDFS was 97%, with 3 (<1%) distant events. Deep dive in the study & biomarkers below🧵1/10 https://t.co/1Jo0Ot03xb

PTarantinoMD's tweet photo. Can ADCs help prevent BC relapse with maintained QoL? Glad to share the final analysis of ATEMPT, out in JCO: among 383 pts with stage I HER2+ BC receiving T-DM1, 5y iDFS was 97%, with 3 (<1%) distant events. Deep dive in the study & biomarkers below🧵1/10 https://t.co/1Jo0Ot03xb https://t.co/MJln1FvtyL

4

167

54

32

34K

1

50

11

7

6K

about 2 years ago

Latest Breast Cancer Research digest by @DFCI_BreastOnc, including our recent publication of #ATEMPT in @JCO_ASCO 👇

British Journal of Sports Medicine (BJSM) @BJSM_BMJ

about 2 years ago

👀this week's #BreastCancer Research Digest for a summary of recent publications from select high-impact journals #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch #BreastOncology

DFCI_BreastOnc's tweet photo. 👀this week's #BreastCancer Research Digest for a summary of recent publications from select high-impact journals #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch #BreastOncology https://t.co/SC8KG19J05

0

25

10

4

5K

0

17

1

3

3K

over 2 years ago

📣 Introducing the first tool to measure adherence to exercise for MSK pain 💪 The Adherence to Exercise for Musculoskeletal Pain Tool (#ATEMPT) will help clinicians measure their patient’s responses to exercise-based treatment ✅ #OpenAccess 👉 https://t.co/q19SXiTmJe

BJSM_BMJ's tweet photo. 📣 Introducing the first tool to measure adherence to exercise for MSK pain 💪

The Adherence to Exercise for Musculoskeletal Pain Tool (#ATEMPT) will help clinicians measure their patient’s responses to exercise-based treatment ✅

#OpenAccess 👉 https://t.co/q19SXiTmJe https://t.co/rQdeKiDIxw

3

122

41

46

19K

British Journal of Sports Medicine (BJSM) @BJSM_BMJ

over 2 years ago

📣 Introducing the first tool to measure adherence to exercise for MSK pain 💪 The Adherence to Exercise for Musculoskeletal Pain Tool (#ATEMPT) will help clinicians measure their patient’s responses to exercise-based treatment ✅ #OpenAccess 👉 https://t.co/q19SXiTmJe

0

144

57

60

24K

over 2 years ago

We are leading a randomized Phase 2 trial for stage 1 HER2+ #breastcancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (#ATEMPT 2.0). For more information call 877-338-7425 or visit: https://t.co/CQRaG5zFfb

0

8

4

0

946

Integrity CE SoMe CME @SoMeCME

about 3 years ago

We are leading a randomized Phase 2 trial for stage 1 HER2+ #breastcancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (#ATEMPT 2.0). For more information call 877-338-7425 or visit: https://t.co/CQRaG5Ad4J @stolaney1

0

15

8

1

3K

Oncology Brothers

@OncBrothers

over 3 years ago

1. #SABCS22 updates w/ @ErikaHamilton9 from @SarahCannonDocs on Her 2 #breastcancer: - #APT and #ATEMPT: de-escalating studies update - #DestinyBreast 02, 03, and 04: TDxD in mBC updates https://t.co/4fKGDZcbOw #bcsm #SABCSUpdate @OncoAlert @SoMeCME @SABCSSanAntonio

over 3 years ago

1/ #SABCSUpdate 📣 #OncTwitter: Clinically relevant updates in HER2+ metastatic #breastcancer w/ @erikahamilton9 & @OncBrothers! Supported by educational grants from Gilead & Lilly. CME ℹ️ https://t.co/SBLP7ItIt3 📊 What is your specialty❓

1

2

0

11K

1

28

10

9

10K

REVEAL GENOMICS @RevealGenomics

over 3 years ago

#SABCS22 Poster Spotlight Discussion: Sara Hurvitz on how #HER2DX may be a useful tool to distinguish patients who need more therapy from those who will do well with less #ATEMPT Clinical Trial conclusions @stolaney1 #PTarantinoMD #precisiononcology #treatmentoptimization

RevealGenomics's tweet photo. #SABCS22 Poster Spotlight Discussion: Sara Hurvitz on how #HER2DX may be a useful tool to distinguish patients who need more therapy from those who will do well with less #ATEMPT Clinical Trial conclusions
@stolaney1
#PTarantinoMD
#precisiononcology
#treatmentoptimization https://t.co/YFwpC1LT3c

0

11

3

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 3 years ago

#ATEMPT also looked at "right sizing" treatment w/ T-DM1 for small #HER2 #bcsm w/ similar fantastic outcomes. 📣ATEMPT2.0 will examine 6 months of T-DM1 as 1 yr was actually a bit harder to tolerate than we expected #SABCS22 @OncoAlert @PTarantinoMD @stolaney1

ErikaHamilton9's tweet photo. #ATEMPT also looked at "right sizing" treatment w/ T-DM1 for small #HER2 #bcsm w/ similar fantastic outcomes.

📣ATEMPT2.0 will examine 6 months of T-DM1 as 1 yr was actually a bit harder to tolerate than we expected

#SABCS22 @OncoAlert

@PTarantinoMD @stolaney1 https://t.co/HhnkwvL4r9

0

26

10

3

0

over 3 years ago

Huge thanks to @SABCSSanAntonio and @AACR for granting me a Travel Award for our abstract on the 5-year outcomes and correlative analyses from #ATEMPT (PI: @stolaney1). Don’t miss the Spotlight Discussion session on Friday, with many important presentations in the HER2+ space!

PTarantinoMD's tweet photo. Huge thanks to @SABCSSanAntonio and @AACR for granting me a Travel Award for our abstract on the 5-year outcomes and correlative analyses from #ATEMPT (PI: @stolaney1). Don’t miss the Spotlight Discussion session on Friday, with many important presentations in the HER2+ space! https://t.co/d9trlkc3bT

0

93

2

1

0

Michelle DeMeo @MKDeMeo

over 3 years ago

So proud of everything from our group at #SABCS2022 - especially #PACE #ATEMPT #TBCRC22 and #APT !

over 3 years ago

#SABCS22 is the largest symposium in translational & clinical research in #BreastCancer and it's starting tomorrow! Here is a list of over 75 presentations, symposia, educational sessions, and poster discussions from @DFCI_BreastOnc faculty you don't want to miss! 🧵A thread 1/9

DFCI_BreastOnc's tweet photo. #SABCS22 is the largest symposium in translational & clinical research in #BreastCancer and it's starting tomorrow! Here is a list of over 75 presentations, symposia, educational sessions, and poster discussions from @DFCI_BreastOnc faculty you don't want to miss! 🧵A thread 1/9 https://t.co/mWAIa03BZW

3

35

7

5

0

5

0

REVEAL GENOMICS @RevealGenomics

over 3 years ago

Don’t miss the #SABCS22 presentations of #APT, #ATEMPT AND #DAPHNE, with validation of HER2DX across cohorts of HER2+ patients treated with modern (neo)adjuvant regimens! @SABCSSanAntonio @DFCI_BreastOnc

PTarantinoMD's tweet photo. Don’t miss the #SABCS22 presentations of #APT, #ATEMPT AND #DAPHNE, with validation of HER2DX across cohorts of HER2+ patients treated with modern (neo)adjuvant regimens! @SABCSSanAntonio @DFCI_BreastOnc https://t.co/O1do5xwsMN

over 3 years ago

🔴Outstanding results for #HER2DX at #SABCS22 : its risk score predicted long-term survival outcomes in clinically low-risk #patients and its pCR score the response to #chemotherapy in combination with #trastuzumab and #pertuzumab 👉🏻 https://t.co/uvW0uN1eCP #breastcancer

RevealGenomics's tweet photo. 🔴Outstanding results for #HER2DX at #SABCS22 : its risk score predicted long-term survival outcomes in clinically low-risk #patients and its pCR score the response to #chemotherapy in combination with #trastuzumab and #pertuzumab 👉🏻 https://t.co/uvW0uN1eCP
#breastcancer https://t.co/uS5etNPLe8

0

19

6

0

22

8

2

0

REVEAL GENOMICS @RevealGenomics

over 3 years ago

Honored to have the opportunity to present the final results of #ATEMPT at the upcoming #SABCS22. Here, a little spoiler on the correlative analyses we conducted in the trial. Stay tuned! 👇

over 3 years ago

🔴 Positive top-line results in APT and ATEMPT trials: #HER2DX risk score was significantly associated with relapse-free interval in #patients with clinically low-risk HER2+ #breastcancer who took part in both trials. Read the press release here: https://t.co/ftdOMLIdfg

RevealGenomics's tweet photo. 🔴 Positive top-line results in APT and ATEMPT trials: #HER2DX risk score was significantly associated with relapse-free interval in #patients with clinically low-risk HER2+ #breastcancer who took part in both trials. Read the press release here: https://t.co/ftdOMLIdfg https://t.co/VF7pHiboXy

4

44

19

1

0

32

3

1

0

over 4 years ago

#ATEMPT is the only trial where patients with early BC received 1 year of adjuvant T-DM1 without any other chemo I’m glad to contribute to this @Nature_NPJ BC work led by @DrRBarroso, showing that adjuvant T-DM1 is associated with an extremely low incidence of cardiotoxicity